Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Ya-Huei Zeng"'
Autor:
Hsu-Heng Yen, Pei-Yuan Su, I.-L.ing Liu, Ya-Huei Zeng, Siou-Ping Huang, Yu-Chun Hsu, Po-Ke Hsu, Yang-Yuan Chen
Publikováno v:
BMC Gastroenterology, Vol 21, Iss 1, Pp 1-7 (2021)
Abstract Background Hepatitis C virus (HCV) is one of the major causes of chronic liver disease, cirrhosis, and liver cancer. Most of the infected people have no clinical symptoms. The current strategy for HCV elimination includes test and treatment.
Externí odkaz:
https://doaj.org/article/133452fe1d8d4790aa5a9cba340b5277
Autor:
Hsu-Heng Yen, Pei-Yuan Su, Siou-Ping Huang, Lisha Wu, Tsui-Chun Hsu, Ya-Huei Zeng, Yang-Yuan Chen
Publikováno v:
PLoS ONE, Vol 16, Iss 5, p e0252286 (2021)
Background/purposeAn increased prevalence of non-alcoholic fatty liver disease (NAFLD) is observed in patients with inflammatory bowel disease (IBD) in Western countries. Both intestinal inflammation and metabolic factors contribute to the pathogenes
Externí odkaz:
https://doaj.org/article/a36101caba7b4924a7de216557bb2e84
Autor:
Hsu-Heng Yen, Pei-Yuan Su, Ya-Huei Zeng, I-Ling Liu, Siou-Ping Huang, Yu-Chun Hsu, Yang-Yuan Chen, Chia-Wei Yang, Shun-Sheng Wu, Kun-Ching Chou
Publikováno v:
PLoS ONE, Vol 15, Iss 8, p e0237582 (2020)
IntroductionChronic hepatitis C virus (HCV) infection is increasingly observed in patients with renal disease. With the introduction of glecaprevir/pibrentasvir (GLE/PIB) as a pan-genotype therapy for HCV, treatment efficacy is expected to rise.Mater
Externí odkaz:
https://doaj.org/article/446aba5b5be84bba8953de266f832d55
Autor:
楊媛淇 Yi-Lin Liou, 曾雅慧 Yuan-Chi Yang, 林靜君 Ya-Huei Zeng, 徐友春 Ching-Chun Lin, 蘇培元 Yu-Chun Hsu, 陳素珊 Pei-Yuan Su, 顏旭亨 Su-Shan Chen
Publikováno v:
醫療品質雜誌. 16:032-037
B、C型肝炎病人需要定期追蹤及檢驗疾病發展狀況，以及早發現肝癌。彰化基督教醫院胃腸肝膽科於2010年開始實行衛生福利部中央健康保險署（下稱健保署）追蹤照護計畫，過程中因病人病
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5305573f1fa4d2741f08da3ad6cb6ab3
https://doi.org/10.53106/199457952022031602005
https://doi.org/10.53106/199457952022031602005
Autor:
Yang-Yuan Chen, Chun-Yu Lin, Hsu-Heng Yen, Pei-Yuan Su, Ya-Huei Zeng, Siou-Ping Huang, I-Ling Liu
Publikováno v:
Journal of Personalized Medicine; Volume 12; Issue 7; Pages: 1026
The rising incidence of fatty liver disease (FLD) poses a health challenge, and is expected to be the leading global cause of liver-related morbidity and mortality in the near future. Early case identification is crucial for disease intervention. A r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7175a10ddbda3373760f2bc1056009c
Autor:
Yang-Yuan Chen, Pei-Yuan Su, Po-Ke Hsu, Ya-Huei Zeng, Siou-Ping Huang, Yu-Chun Hsu, I.-L.ing Liu, Hsu-Heng Yen
Publikováno v:
BMC Gastroenterology, Vol 21, Iss 1, Pp 1-7 (2021)
BMC Gastroenterology
BMC Gastroenterology
Background Hepatitis C virus (HCV) is one of the major causes of chronic liver disease, cirrhosis, and liver cancer. Most of the infected people have no clinical symptoms. The current strategy for HCV elimination includes test and treatment. In this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64a15406d71d6f612428c8c03734fc95
https://doaj.org/article/133452fe1d8d4790aa5a9cba340b5277
https://doaj.org/article/133452fe1d8d4790aa5a9cba340b5277
Autor:
Hsu-Heng Yen, Yang-Yuan Chen, Jun-Hung Lai, Hung-Ming Chen, Chih-Ta Yao, Siou-Ping Huang, I-Ling Liu, Ya-Huei Zeng, Fang-Chi Yang, Fu-Yuan Siao, Mei-Wen Chen, Pei-Yuan Su
Publikováno v:
Journal of Clinical Medicine; Volume 11; Issue 7; Pages: 1853
Although the pan-genotypic direct-acting antiviral regimen was approved for treating chronic hepatitis C infection regardless of the hepatitis C virus (HCV) genotype, real-world data on its effectiveness against mixed-genotype or genotype-undetermine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffa8f351b6e4766c7c99bf3bcb1f4db7
Autor:
Chia-Wei Yang, I-Ling Liu, Shun-Sheng Wu, Kun-Ching Chou, Siou-Ping Huang, Pei-Yuan Su, Hsu-Heng Yen, Yu-Chun Hsu, Yang-Yuan Chen, Ya-Huei Zeng
Publikováno v:
PLoS ONE
PLoS ONE, Vol 15, Iss 8, p e0237582 (2020)
PLoS ONE, Vol 15, Iss 8, p e0237582 (2020)
IntroductionChronic hepatitis C virus (HCV) infection is increasingly observed in patients with renal disease. With the introduction of glecaprevir/pibrentasvir (GLE/PIB) as a pan-genotype therapy for HCV, treatment efficacy is expected to rise.Mater
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::606225606e4f917e5b8c25727777c2cd
http://europepmc.org/articles/PMC7425913
http://europepmc.org/articles/PMC7425913
Autor:
Shun-Sheng Wu, Fu-Yuan Siao, Hsu-Heng Yen, Pei-Yuan Su, Jun-Hung Lai, Yu-Chun Hsu, Siou-Ping Huang, I-Ling Liu, Yang-Yuan Chen, Hung-Ming Chen, Chih-Ta Yao, Ya-Huei Zeng
Publikováno v:
Journal of Clinical Medicine
Journal of Clinical Medicine, Vol 10, Iss 5236, p 5236 (2021)
Volume 10
Issue 22
Journal of Clinical Medicine, Vol 10, Iss 5236, p 5236 (2021)
Volume 10
Issue 22
Background: Glecaprevir/pibrentasvir is a protease inhibitor-containing pangenotypic direct-acting antiviral regimen that has been approved for the treatment of chronic hepatitis C. The present study aimed to evaluate the safety and efficacy of gleca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bada9497f53273e08c50097b64e72b7
https://doi.org/10.3390/jcm10225236
https://doi.org/10.3390/jcm10225236
Autor:
Ya-Huei Zeng, Li-Sha Wu, Siou-Ping Huang, Hsu-Heng Yen, Pei-Yuan Su, Tsui-Chun Hsu, Yang-Yuan Chen
Publikováno v:
PLoS ONE, Vol 16, Iss 5, p e0252286 (2021)
PLoS ONE
PLoS ONE
Background/purpose An increased prevalence of non-alcoholic fatty liver disease (NAFLD) is observed in patients with inflammatory bowel disease (IBD) in Western countries. Both intestinal inflammation and metabolic factors contribute to the pathogene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e10e963e6cfaaed5efdbc3297757fe42
https://doi.org/10.1371/journal.pone.0252286
https://doi.org/10.1371/journal.pone.0252286